Inogen, Inc. (INGN)

INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.

Campbell and CO Investment Adviser LLC reduced its holdings in Inogen, Inc (NASDAQ: INGN) by 10.7% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,244 shares of the medical technology company's stock after selling 7,359 shares during the quarter. Campbell and CO

Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Inogen (INGN) continues its turnaround, showing progress in revenue growth and margins, but the pace remains slower and riskier than the market desires. INGN posted positive adjusted EBITDA and raised full-year guidance, despite mixed quarterly results and ongoing volatility in direct-to-consumer and rental segments. The company's strong market position, new product launches, and partnerships offer long-term growth potential, especially as patients consistently prefer portable solutions.

INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.

Inogen, Inc. ( INGN ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Lorna Williams Kevin Smith - President, CEO & Director Michael Bourque - Executive VP, CFO & Corporate Treasurer Conference Call Participants Joseph Conway - Needham & Company, LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Presentation Operator Welcome to Inogen's Third Quarter 2025 Earnings Conference Call.

Inogen (INGN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.25 per share a year ago.

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Third Quarter 2025 Financial Results Delivered seventh consecutive quarter of mid-single-digit revenue growth.

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. On the same day, the Company will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961.

Inogen (INGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer.

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Inogen (INGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Teleflex, Integer Holdings and Inogen are defying tariff and supply chain headwinds with genAI-driven momentum within the Medical Instruments industry.

The mean of analysts' price targets for Inogen (INGN) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.